Novo Nordisk's Record Pill Launch Meets a Cybersecurity Reality Check
16.06.2026 - 03:33:20 | boerse-global.de
The Danish drugmaker is living two parallel stories this quarter. One is about the Wayovy pill smashing prescription records — the strongest volume launch the US pharmaceutical market has seen in years. The other is about a cyberattack that has exposed sensitive clinical trial data and left investors weighing a new category of risk.
Novo Nordisk’s oral semaglutide reached three million prescriptions in just over five months, with the first million written within twelve weeks of launch and the next two million following in just ten more weeks. More than 80% of those patients had never taken a GLP-1 therapy before, underscoring the pill’s ability to expand the market rather than merely cannibalise the injection. The commercial momentum translated directly into the bottom line: first-quarter revenue from the Wegovy tablet came in at 2.26 billion Danish kroner, nearly double the 1.16 billion kroner analysts at Jefferies had anticipated.
The stellar launch has allowed management to nudge its full?year guidance higher. Novo Nordisk now expects revenue and operating profit to decline by 4% to 12% in 2026, an improvement from the prior range of 5% to 13%. Still, the outlook remains firmly in contraction territory, reflecting the headwinds the company faces. Price agreements with the US government under the “Most Favoured Nation” policy, Medicaid restrictions, and the approaching loss of semaglutide exclusivity are all weighing on revenue prospects. Last November the group already cut prices for Wegovy and Ozempic for Medicare beneficiaries and cash?paying patients.
From 1 July 2026 a new Medicare bridge programme will cap patients’ monthly out?of?pocket cost for both Wegovy tablets and injections at $50. Later this year, Novo Nordisk plans the first international launches of the oral Wegovy, starting with the already?approved rollout in the United Arab Emirates.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
While the commercial franchise is expanding, the pipeline continues to generate data. At the American Diabetes Association’s annual meeting in New Orleans in early June, Novo Nordisk presented Phase?3 results from the Reimagine?1?3 studies. The data showed significant reductions in HbA1c and body weight in adults with type?2 diabetes, hitting all primary and secondary endpoints. The findings were simultaneously published in The Lancet and The Lancet Diabetes & Endocrinology.
That same week, however, the company disclosed a cybersecurity incident that had compromised internal IT systems. Attackers stole pseudonymised patient data — study IDs, sex, year of birth, biomarkers, and lifestyle factors such as BMI and smoking status — but not names. More worryingly, non?pseudonymised contact details of healthcare providers, including names, registration numbers, email addresses and phone numbers, were also taken. Novo Nordisk has taken affected systems offline and stressed that core operations are unaffected, but security experts warn the stolen data could fuel targeted phishing campaigns.
In the midst of these events, Novo Nordisk continues to buy back its own shares at a steady clip. Since the current programme launched on 4?February 2026, the company has repurchased nearly 19.9?million B?shares at an average price of 264.99?kroner, for a total outlay of about 5.3?billion kroner. The tranche, initiated in May, allows for buybacks of up to 11.2?billion kroner through February 2027. Novo Nordisk now holds 37.1?million treasury B?shares, equivalent to 0.8% of its share capital.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Adding a side note to the executive suite, former chief executive Lars Fruergaard Jørgensen has ruled out returning to helm another large corporation. Having stepped down in August 2025 after steering the company through the GLP?1 boom, he plans to focus on smaller companies and advisory roles — a personal decision with no immediate operational impact.
The stock closed on Monday at €38.02, up 6.5% on the week, and was recently quoted at €37.92. That leaves it 43% below the June 2025 peak of €66.70 but 25% above the March trough of €30.25. Whether the record launch, pipeline progress and buyback firepower can offset the structural price pressure and the long?term implications of the cyber breach will become clearer when Novo Nordisk reports half?year results, expected at the end of July.
Ad
Novo Nordisk Stock: New Analysis - 16 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
